NCT05565092终止2 期
A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Participants With Sickle Cell Disease
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events
研究概览
简要总结
The primary objective of this study is to assess the safety and tolerability of ALXN1820 SC (subcutaneous) in participants with SCD (Sickle Cell Disease).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of SCD (HbSS, or HbSβ0-thalassemia).
- •Body weight ≥ 40 kg (inclusive) at Screening.
- •Must follow protocol-specified contraception guidance while on treatment and for up to 6 months after last dose.
- •Hemoglobin between 5.5 and 10 g/dL at Screening
- •Have had 1 to 10 VOCs in the past 12 months.
- •Patients receiving hydroxyurea must have been on a stable dose for ≥ 3 months prior to providing informed consent, with no anticipated need for dose adjustment during the study.
- •Patients will be vaccinated with MCV4 and serogroup B meningococcal vaccinations at least 14 days before dosing, if not already vaccinated within 3 years before the first dose.
- •Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae vaccination are up to date according to current national/local vaccination guidelines for patients with SCD.
排除标准
- •Planned initiation, termination, or dose alteration of hydroxyurea during the study.
- •Receiving Voxelotor (OXBRYTA) or crizanlizumab (ADAKVEO) within 60 days of providing informed consent.
- •Receiving treatment with recombinant human erythropoetins (eg, epoetin alfa).
- •Treated with complement inhibitors within 6 months prior to the first dose.
- •Patients who are on chronic transfusion or receive a transfusion within 60 days of first dose.
- •Any significant disease or disorder which, in the opinion of the Investigator, may put the participant at risk.
- •Hepatitis B (positive hepatitis surface antigen [HBsAg] or positive core antibody (anti-HBc) with negative surface antibody [anti-HBs]) or hepatitis C viral infection (hepatitis C virus [HCV] antibody positive, except for patients with documented successful treatment and documented sustained virologic response) at Screening.
- •Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing.
- •Participation (ie, last protocol-required study visit) in a clinical study within 90 days or 5 half-lives of the investigational agent, whichever is longer, before initiation of dosing on Day
- •Participation in more than 1 clinical study of a monoclonal antibody (mAb), or participation in a clinical study of a mAb within the 6 months or 5 half-lives of the mAb, whichever is longer, prior to Screening, during which the participant was exposed to the active study drug.
- •Severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2 ) or on chronic dialysis.
- •History of allergy or hypersensitivity to excipients of ALXN1820 (eg, polysorbate 80).
- •History of complement deficiency.
- •History of N meningitidis, S pneumoniae, or H influenzae infection.
- •History of malignancy with the exception of a nonmelanoma skin cancer or carcinoma in situ of the cervix that has been treated with no evidence of recurrence within 5 years.
- •Participants who are pregnant or breastfeeding.
研究组 & 干预措施
ALXN1820 300 mg once weekly
Experimental
Participants will receive 300 milligrams (mg) once weekly (QW).
干预措施: ALXN1820 (Drug)
ALXN1820 600 mg once every 4 weeks
Experimental
Participants will receive 600 mg once every 4 weeks (Q4W).
干预措施: ALXN1820 (Drug)
ALXN1820 300 mg once every 2 weeks (Optional cohort)
Experimental
Participants will receive 300 mg once every 2 weeks (Q2W).
干预措施: ALXN1820 (Drug)
结局指标
主要结局
Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events
时间窗: Baseline through Day 211 (Cohorts 1 and 2) and through Day 169 (Optional Cohort 3)
次要结局
- Pharmacokinetics: Serum ALXN1820 Concentration(Baseline through Day 211 (Cohorts 1 and 2) and through Day 169 (Optional Cohort 3))
- Change From Baseline in Serum Concentration of Total and Free Properdin Through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3)(Baseline through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3))
- Change From Baseline Complement Alternative Pathway Activity Through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3)(Baseline through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3))
- Change From Baseline in Complement Biomarkers Through Week 12 (Cohorts 1 and 2)(Baseline, Week 12)
- Change From Baseline in Hemoglobin Level at Week 12 (Cohorts 1 and 2)(Baseline, Week 12)
- Change From Baseline in Hemolysis Markers at Week 12 (Cohorts 1 and 2)(Baseline, Week 12)
- Change From Baseline in Hemopexin at Week 12 (Cohorts 1 and 2)(Baseline, Week 12)
- Number of Participants With Antidrug Antibodies to ALXN1820(Baseline through Day 211 (Cohorts 1 and 2) and through Day 169 (Optional Cohort 3))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of LY2439821 in Rheumatoid ArthritisRheumatoid ArthritisNCT01236118Eli Lilly and Company28
已完成
1 期
A Treatment Study of Mucopolysaccharidosis Type IIIBMPS III BMucopolysaccharidosis Type IIIBNCT02754076Allievex Corporation23
已完成
2 期
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT00620321Eli Lilly and Company24
已完成
2 期
Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1Autosomal Dominant Hypocalcemia (ADH)Autosomal Dominant Hypocalcemia Type 1 (ADH1)NCT04581629Calcilytix Therapeutics, Inc., a BridgeBio company13
终止
1 期
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MMB-cell Chronic Lymphocytic LeukemiaMultiple MyelomaNCT00648739Alexion Pharmaceuticals, Inc.26